Michelle Tomlinson-Phelan, DO
Family Medicine · East Brunswick, NJNPI 1801859517
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 259 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 20.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $958 and has fallen 76.8% since, to $222 in 2025.
Across 259 payments — averaging $13.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$727
- Novo Nordisk$551
- AstraZeneca$406
- Lilly USA, LLC$306
- Takeda Pharmaceuticals U.S.A., Inc.$175
- Otsuka America Pharmaceutical, Inc.$164
- plus $1K from 28 others
What the payments were for
- Food & beverage$3,610100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 52 | $727 |
| Novo Nordisk | 41 | $551 |
| AstraZeneca | 29 | $406 |
| Lilly USA, LLC | 21 | $306 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $175 |
| Otsuka America Pharmaceutical, Inc. | 12 | $164 |
| Merck | 9 | $122 |
| Sanofi-aventis U.S. LLC | 7 | $102 |
| Bayer | 5 | $93 |
| Amgen | 6 | $86 |
| Amarin Pharma, Inc. | 6 | $81 |
| Boehringer Ingelheim | 6 | $80 |
| Johnson & Johnson | 6 | $79 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $71 |
| Lundbeck LLC | 4 | $62 |
| Pfizer | 4 | $54 |
| GSK | 4 | $54 |
| Kowa Pharmaceuticals America, Inc. | 4 | $51 |
| Daiichi Sankyo Inc. | 3 | $44 |
| Sunovion Pharmaceuticals Inc. | 4 | $42 |
| Exact Sciences | 2 | $35 |
| Neurocrine Biosciences, Inc. | 3 | $35 |
| Jazz Pharmaceuticals Inc. | 2 | $24 |
| Biogen | 1 | $22 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Genentech USA, Inc. | 1 | $15 |
| Avanir Pharmaceuticals, Inc. | 1 | $15 |
| Indivior Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Eisai Inc. | 1 | $14 |
| Alkermes, Inc. | 1 | $14 |
| Seqirus USA Inc | 1 | $12 |
| Dermira, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,610 in reported general payments places this provider in the 85th percentile of 2,084 family medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rosuvastatin Calcium | 43 | $1,083 |
| Gabapentin | 28 | $726 |
| Levothyroxine Sodium | 45 | $696 |
| Metoprolol Succinate | 14 | $682 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 15 | $611 |
| Atorvastatin Calcium | 37 | $390 |
| Pantoprazole Sodium | 14 | $347 |
| Zolpidem Tartrate | 13 | $335 |
| Metformin Hcl | 22 | $256 |
| Montelukast Sodium | 14 | $185 |
| ClopidogrelClopidogrel Bisulfate | 11 | $184 |
| Hydrochlorothiazide | 24 | $175 |
| Meloxicam | 24 | $158 |
| Simvastatin | 24 | $129 |
| Amlodipine Besylate | 15 | $126 |
Paid to pharmacies, not to this prescriber.
Other family medicine in East Brunswick
- Mikhail VarshavskiChatham$1.4M
- Janet ColeFar Hills$466K
- Matthew PintoMarlton$239K
- Jennifer CaudleSewell$226K
- Jeffrey LevineNew Brunswick$195K
- Jennifer AmicoNew Brunswick$159K
- Dena LacaraFairfield$122K
- Gaurang BrahmbhattHoboken$89K
- Juan LatorreHoboken$71K
- Sally MravcakJersey City$64K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.